GW Pharmaceuticals PLC Company Profile (NASDAQ:GWPH)

GW Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC (NASDAQ:GWPH) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.70) EPS for the quarter, missing the Zacks' consensus estimate of ($1.50) by $0.20. The firm had revenue of $2.04 million for the quarter, compared to analyst estimates of $2.07 million. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The business's revenue was down 23.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) EPS. View GW Pharmaceuticals PLC's Earnings History.

8 equities research analysts have issued 12-month price targets for GW Pharmaceuticals PLC's stock. Their forecasts range from $135.00 to $208.00. On average, they anticipate GW Pharmaceuticals PLC's share price to reach $161.71 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals PLC.

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC stock:

• 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (7/17/2017)
• 2. Maxim Group analysts commented, "GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM)." (5/25/2017)
• 3. Cantor Fitzgerald analysts commented, "NDA Filing Expected Mid-2017. GWPH expects to complete its filing in the U.S. shortly and noted two key portions in progress: 1) an integrated safety analysis of over 1,500 treated patients from clinical studies and the expanded access program, and 2) manufacturing data from the company’s manufacturing processes, including scaled materials. These elements will be the two determining factors of the timing of the NDA submission, which is expected in the middle of the year. Following the U.S. submission, GW expects to submit its MAA filing in 2H17 and plans to meet with the EMA in the near term. Pre-commercialization Activities Intensify. Greenwich Biosciences, the U.S. subsidiary of GW, is progressing with a pre-commercial strategy of expanding its team for the drug launch of Epidiolex. GW guided for a commercial team consisting of 15 medical-science liaisons by the end of 2017 and a sales force of 50-60 sales representatives to reach 4,000-5,000 targeted U.S. physicians. In addition, the company has begun to engage payors on awareness of patient need, Epidiolex, and pricing. We believe these efforts will set a meaningful foundation for Epidiolex’s commercial launch, which we estimate will initiate in 2018. Model Update. Following F2Q17 financial results, we have updated our model to reflect recent quarterly results and future expectations of operational expenditures." (5/9/2017)

Some companies that are related to GW Pharmaceuticals PLC include bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Beigene Ltd (BGNE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Prothena Corporation PLC (PRTA), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON), AveXis (AVXS), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO) and Radius Health (RDUS).

GW Pharmaceuticals PLC's management team includes the folowing people:

• Geoffrey W. Guy, Executive Chairman of the Board
• Justin Gover, Chief Executive Officer, Director
• Adam David George, Chief Financial Officer, Company Secretary, Director
• Christopher John Tovey, Chief Operating Officer, Executive Director
• Julian S. Gangolli, Executive Director
• James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
• Cabot Brown, Non-Executive Independent Director
• Thomas Gerard Lynch, Non-Executive Independent Director

GW Pharmaceuticals PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include Rothschild Investment Corp IL (0.08%), US Bancorp DE (0.05%), Woodstock Corp (0.02%), Fox Run Management L.L.C. (0.02%), Aperio Group LLC (0.01%) and Eqis Capital Management Inc. (0.01%). View Institutional Ownership Trends for GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including Profit Investment Management LLC, Bank of Montreal Can and US Bancorp DE. View Insider Buying and Selling for GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC's stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL, Fox Run Management L.L.C., Quantitative Systematic Strategies LLC, Aperio Group LLC, Eqis Capital Management Inc. and Creative Planning. View Insider Buying and Selling for GW Pharmaceuticals PLC.

Shares of GW Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GW Pharmaceuticals PLC stock can currently be purchased for approximately $114.92.